BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”-Reference-Cited by-同舟云学术

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”

Published:2022-10-08 Issue:3 Volume:12 Page:3180-3184
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Di Giusto Sara¹,Toffoletti Eleonora¹²,Bonifacio Massimiliano³^ORCID,Binotto Gianni⁴,Miggiano Maria Cristina⁵,Calistri Elisabetta⁶,Stulle Manuela⁷,Ermacora Anna⁸,Stella Rossella¹,Scaffidi Luigi³,D'Amore Fabio⁴,Scotton Giorgia⁴,Griguolo Davide⁷,De Matteis Giovanna⁹,Bertorelle Roberta¹⁰,Krampera Mauro³,Semenzato Gianpietro⁴,Fanin Renato¹²,Damiani Daniela¹²^ORCID,Tiribelli Mario¹²^ORCID

Affiliation:

1. Division of Hematology and BMT Azienda Sanitaria Universitaria Friuli Centrale Udine Italy

2. Department of Medical Area University of Udine Udine Italy

3. Department of Medicine, Section of Hematology University of Verona Verona Italy

4. Department of Medicine, Hematology and Clinical Immunology University of Padua Paduva Italy

5. Department of Hematology San Bortolo Hospital Vicenza Italy

6. Hematology Unit Ca’ Foncello Hospital Treviso Italy

7. Hematology Unit Azienda Sanitaria Universitaria Giuliano‐Isontina Trieste Italy

8. Division of Internal Medicine Azienda Ospedaliera S. Maria Angeli Pordenone Italy

9. Department of Life Sciences, Section of Biochemistry University of Verona Verona Italy

10. Immunology and Molecular Oncology Istituto Oncologico Veneto Padua Italy

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5158

Reference15 articles.

1. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

2. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

3. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice

4. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

5. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety;Expert Opinion on Drug Safety;2024-06-17

2. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements;Blood Cancer Journal;2024-03-26

3. One‐month qRT‐PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission;European Journal of Haematology;2023-08-16

4. Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study;International Journal of Molecular Sciences;2023-06-14

5. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia;European Journal of Haematology;2022-12-13